The latest price target for Intensity Therapeutics (NASDAQ:INTS) was reported by Alliance Global Partners on January 13, 2025. The analyst firm set a price target for $8.50 expecting INTS to rise to within 12 months (a possible 286.36% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Intensity Therapeutics (NASDAQ:INTS) was provided by Alliance Global Partners, and Intensity Therapeutics initiated their buy rating.

There is no last upgrade for Intensity Therapeutics

There is no last downgrade for Intensity Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intensity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intensity Therapeutics was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.

While ratings are subjective and will change, the latest Intensity Therapeutics (INTS) rating was a initiated with a price target of $0.00 to $8.50. The current price Intensity Therapeutics (INTS) is trading at is $2.20, which is within the analyst’s predicted range.